We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+8.72%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
-$17.9M
(-24%)
Cap. Flow
-$4.42M
Cap. Flow
% of AUM
-7.61%
Top 10 Holdings %
Top 10 Hldgs %
43.93%
Holding
340
New
63
Increased
59
Reduced
56
Closed
151
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$2.31M |
| 2 |
Amgen
AMGN
|
+$1.97M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$1.79M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$1.56M |
| 5 |
Clorox
CLX
|
+$1.3M |
Top Sells
| 1 |
Abbott
ABT
|
+$5.02M |
| 2 |
Akebia Therapeutics
AKBA
|
+$3.63M |
| 3 |
FL
Foot Locker
FL
|
+$2.12M |
| 4 |
General Mills
GIS
|
+$2.03M |
| 5 |
lululemon athletica
LULU
|
+$1.38M |
Sector Composition
| 1 | Healthcare | 37.51% |
| 2 | Consumer Staples | 17.11% |
| 3 | Consumer Discretionary | 2.69% |
| 4 | Communication Services | 1.36% |
| 5 | Materials | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
76
PUT
DELISTED
Sage Therapeutics
SAGE
| $108K | 0.19% |
74,000
+54,700
| +283% | +$3.95M |
|
|
MON
77
CALL
DELISTED
Monsanto Co
MON
| $107K | 0.18% |
24,400
-22,300
| -48% | -$2.6M |
|
|
OTIC
78
CALL
DELISTED
Otonomy, Inc.
OTIC
| $106K | 0.18% |
33,500
+31,800
| +1,871% | +$443K |
|
79
CALL
Illumina
ILMN
$28.8B
| $101K | 0.17% |
+7,299
| New | +$1.26M |
|
80
PUT
Kimberly-Clark
KMB
$36.2B
| $97K | 0.17% |
16,900
-20,100
| -54% | -$2.62M |
|
|
K
81
PUT
DELISTED
Kellanova
K
| $96K | 0.17% |
25,667
-92,868
| -78% | -$6.25M |
|
82
PepsiCo
PEP
$190B
| $96K | 0.17% |
+829
| New | +$95.1K |
|
83
PUT
Vertex Pharmaceuticals
VRTX
$123B
| $96K | 0.17% |
39,700
-10,200
| -20% | -$1.23M |
|
|
84
PUT
PepsiCo
PEP
$190B
| $95K | 0.16% |
+45,000
| New | +$5.16M |
|
85
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $94K | 0.16% |
45,000
+35,000
| +350% | +$2.48M |
|
|
86
CALL
iShares Biotechnology ETF
IBB
$9.23B
| $93K | 0.16% |
45,000
+30,000
| +200% | +$2.95M |
|
87
CALL
Hershey
HSY
$35.4B
| $92K | 0.16% |
57,000
+22,600
| +66% | +$2.49M |
|
|
TWX
88
CALL
DELISTED
Time Warner Inc
TWX
| $89K | 0.15% |
54,200
+31,000
| +134% | +$3.07M |
|
89
CALL
AstraZeneca
AZN
$263B
| $87K | 0.15% |
+30,050
| New | +$1.96M |
|
|
TSRO
90
CALL
DELISTED
TESARO, Inc.
TSRO
| $87K | 0.15% |
20,800
+3,000
| +17% | +$434K |
|
91
CALL
Bausch Health
BHC
$1.84B
| $86K | 0.15% |
39,600
+9,600
| +32% | +$115K |
|
92
PUT
Alnylam Pharmaceuticals
ALNY
$37.8B
| $85K | 0.15% |
20,000
+6,800
| +52% | +$435K |
|
|
ZSAN
93
DELISTED
Zosano Pharma Corporation
ZSAN
| $85K | 0.15% |
86
| – | – |
|
94
PUT
Colgate-Palmolive
CL
$75.3B
| $82K | 0.14% |
33,500
+11,000
| +49% | +$817K |
|
95
CALL
Rocket Pharmaceuticals
RCKT
$372M
| $71K | 0.12% |
+27,375
| New | +$204K |
|
96
CALL
Karyopharm Therapeutics
KPTI
$213M
| $69K | 0.12% |
8,413
+5,620
| +201% | +$832K |
|
97
CALL
PayPal
PYPL
$50B
| $66K | 0.11% |
+40,000
| New | +$1.97M |
|
98
CALL
Sarepta Therapeutics
SRPT
$1.82B
| $63K | 0.11% |
16,300
+300
| +2% | +$9.77K |
|
99
BioCryst Pharmaceuticals
BCRX
$2.31B
| $62K | 0.11% |
+11,240
| New | +$68.5K |
|
100
PUT
Bristol-Myers Squibb
BMY
$124B
| $62K | 0.11% |
29,800
-14,800
| -33% | -$805K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2017 Portfolio in Review
As of Q2 2017, FT Options held 340 positions worth $58.1M, down 24% from $76M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
FT Options withdrew a net $4.42M in Q2 2017, closing 151 positions and reducing 56 holdings. Its most notable exit was Foot Locker, an estimated $2.12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, FT Options opened a new position in Amgen worth $2.08M.
- FT Options's largest Q2 2017 buy was Amgen: 12,082 shares worth $2.08M.
- FT Options added most to Clovis Oncology, Inc. in Q2 2017, an estimated $2.31M increase.
- FT Options's biggest Q2 2017 reduction was Abbott, cutting an estimated $5.02M.
- FT Options fully exited Foot Locker in Q2 2017, selling an estimated $2.12M.
- FT Options's ten largest holdings make up 44% of its $58.1M portfolio in Q2 2017.
- FT Options opened 63 new positions and closed 151 in Q2 2017.
- FT Options's portfolio value fell 24% quarter-over-quarter to $58.1M.
Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.